DXCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Dexcom Inc (DXCM) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive growth trends, and a favorable market position in diabetes management. Despite short-term technical weakness, the long-term outlook and analyst sentiment support a buy decision.
The technical indicators show a bearish trend with MACD negatively expanding, RSI at 27.173 (neutral zone), and moving averages indicating weakness (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 61.19, with resistance at 63.433. Short-term price action suggests limited downside risk but no immediate bullish reversal signal.
Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, showcasing strong performance in diabetes management. The company sees untapped global market potential despite concerns over GLP-1 weight loss drugs. Financials show significant YoY growth in revenue (+13.12%), net income (+76.20%), and EPS (+81.08%). Analysts maintain a generally positive outlook with multiple price target increases.
Technical indicators are bearish, and the stock has experienced a slight decline in recent trading sessions. There are no significant hedge fund or insider trading trends to indicate strong buying interest.
In Q4 2025, Dexcom reported revenue of $1.2596 billion (+13.12% YoY), net income of $267.3 million (+76.20% YoY), EPS of $0.67 (+81.08% YoY), and gross margin of 70.3% (+10.36% YoY). These figures highlight robust financial health and growth.
Analysts are generally positive on Dexcom. Recent updates include BTIG lowering the price target to $80 (from $85) with a Buy rating, Citi raising the target to $84 (from $77) with a Buy rating, and Mizuho raising the target to $90 (from $78) with an Outperform rating. The consensus reflects confidence in the company's long-term prospects.
